Carmot Therapeutics, Inc.

Millennium Pharmaceuticals Limited

Sunesis Pharmaceuticals, Inc.

Daniel Erlanson

Gnanasambandam Kumaravel

Kevin Guckian

Deping Wang

Daniel M Scott

Wen-Cherng Lee

Edward Yin-Shiang Lin

Jermaine Thomas

Lei Zhang

Lihong Sun

Timothy Raymond Chan

Stig Hansen

Joseph Arndt

Raymond V Fucini

Shyam Krishnan

Steven Sethofer

Jeff Iwig

Enrique Moya

Kurt Van Vloten

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt) that modulate (e.g., agonize or partially agonize or antagonize) glucagon-like peptide-1 receptor ('GLP-1R') and/or the gastric inhibitory polypeptide receptor (“GIPR”). The chemical entities are useful, e.g., for treating a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, modulation results in enhancement of (e.g., increases) existing levels (e.g., normal or below normal levels) of GLP-1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

Modulators of G-protein coupled receptors

Growing community of inventors

San Francisco, CA, United States of America

Daniel Erlanson